Journal article
Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy
Immunotherapy, Vol.9(10), pp.837-849
08/01/2017
DOI: 10.2217/imt-2017-0055
PMCID: PMC5941714
PMID: 28877635
Abstract
The recent tremendous successes in clinical trials take cancer immunotherapy into a new era and have attracted major attention from both academia and industry. Among the variety of immunotherapy strategies developed to boost patients’ own immune systems to fight against malignant cells, the pathogen-based and adoptive cell transfer therapies have shown the most promise for treating multiple types of cancer. Pathogen-based therapies could either break the immune tolerance to enhance the effectiveness of cancer vaccines or directly infect and kill cancer cells. Adoptive cell transfer can induce a strong durable antitumor response, with recent advances including engineering dual specificity into T cells to recognize multiple antigens and improving the metabolic fitness of transferred cells. In this review, we focus on the recent prospects in these two areas and summarize some ongoing studies that represent potential advancements for anticancer immunotherapy, including testing combinations of these two strategies.
Details
- Title: Subtitle
- Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy
- Creators
- Gang Xin - Gulf Coast Regional Blood CenterDavid M Schauder - Medical College of WisconsinRyan Zander - Gulf Coast Regional Blood CenterWeiguo Cui - Medical College of Wisconsin
- Resource Type
- Journal article
- Publication Details
- Immunotherapy, Vol.9(10), pp.837-849
- Publisher
- Future Medicine Ltd
- DOI
- 10.2217/imt-2017-0055
- PMID
- 28877635
- PMCID
- PMC5941714
- ISSN
- 1750-743X
- eISSN
- 1750-7448
- Alternative title
- Xin, Schauder, Zander & Cui
- Language
- English
- Date published
- 08/01/2017
- Academic Unit
- Microbiology and Immunology
- Record Identifier
- 9984297332402771
Metrics
4 Record Views